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Abstract
Background: Study aimed at investigation of pathogenic role and prognostic value of several selected
cerebrospinal fluid acute phase factors that can reflect the severity of ischemic brain damage.
Methods: Ninety five acute ischemic stroke patients were investigated. Ischemic region visualized at the twenty
fourth hour by conventional Magnetic Resonance Imaging. Stroke severity evaluated by National Institute Health
Stroke Scale. One month outcome of disease was assessed by Barthel Index. Cerebrospinal fluid was taken at the
sixth hour of stroke onset. CSF pro- and anti-inflammatory cytokines were studied by Enzyme Linked
Immunosorbent Assay. Nitric Oxide and Lipoperoxide radical were measured by Electron Paramagnetic Resonance.
CSF Nitrate levels were detected using the Griess reagent. Statistics performed by SPSS-11.0.
Results: At the sixth hour of stroke onset, cerebrospinal fluid cytokine levels were elevated in patients against
controls. Severe stroke patients had increased interleukin-6 content compared to less severe strokes (P < 0.05).
Cerebrospinal fluid Electron Paramagnetic Resonance signal of nitric oxide was increased in patients against
controls. Severe stroke group had an elevated Electron Paramagnetic Resonance signal of lipoperoxiradical
compared to less severe stroke. Cerebrospinal fluid nitrate levels in less severe stroke patients were higher than
those for severe stroke and control. Positive correlation was established between the initial interleukin-6 content
and ischemic lesion size as well as with National Institute Health Stroke Scale score on the seventh day. Initial
interleukin-6 and nitrate levels in cerebrospinal fluid found to be significant for functional outcome of stroke at one
month.
Conclusion: According to present study the cerebrospinal fluid contents of interleukin-6 and nitrates seem to be
the most reliable prognostic factors in acute phase of ischemic stroke.
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Background
Modern concepts of acute cerebral ischemia highlight
t h er o l eo fn e u r o v a s c u l a ru n i t sa n de m p h a s i z et h e
importance of integrative tissue responses that result
from dynamic interactions of endothelial cells, vascular
sooth muscles, matrix elements, astroglia, microglia and
neurons. By means of inflammatory stimuli and exci-
toxicity, such interactions create many sources of free
toxic radicals and reactive oxygen spices [1].
In physiological conditions, endogenous protective
mechanisms stabilize the levels of free oxygen radicals
and reduce the oxidative/nitrosative stress reaction. In
conditions of severe ischemia, rapid failure of the anti-
oxidation protective system assists in the accumulation
of arachidonic acid, prostaglandins, superoxide anion,
NO and other aggressive substrates, which lead to the
destabilization of cellular membranes, further damage of
the blood-brain barrier, disintegration of DNA and, ulti-
mately, to neuronal death [2]. Current therapeutic
options for acute brain ischemia are concentrated on
thrombolytic treatment, but this therapy is restricted to
a small proportion of patients [3]. There is a need to
d e v i s eam o r ee f f e c t i v ep r o t e c t i v ea n dr e p a i rs t r a t e g y
and cellular treatment. The precise neurochemical
alterations that take place in human’s stroke still remain
to be clarified and the cerebrospinal fluid (CSF) is the
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biochemical changes in the ischemic brain tissue. The
purpose of the present research was to investigate the
importance and prognostic value of several selected CSF
acute phase factors that are known to reflect the severity
of ischemic brain damage.
Methods
A total of 95 acute ischemic stroke patients, 54 female
and 41 male, aged 45-70 years, who had been admitted
to the Neurological Clinic of Tbilisi State Medical
University during 2005-2009 were studied. Exclusion
criteria comprised acute inflammatory and autoimmune
disorders, severe somatic pathology, cancer, coma, space
occupying hemispheric and cerebellar ischemic strokes.
Patients and controls that used the anti-inflammatory
medications for the 1-year period prior to the current
research were also excluded from the study. Upon
admission, a conventional CT scan was performed to
exclude a brain hemorrhage. The control group con-
sisted of 25 age-matched patients with vertebral disco-
pathies, who showed no signs of cerebrovascular
pathology. The local ethics committee approved the pro-
tocol, and informed consent was obtained from all parti-
cipants or their surrogates
The etiology of stroke was classified according to
TOAST criteria [4]. Medical records were retrospec-
tively reviewed for selected non-modifiable and modifi-
able risk factors of stroke, including age, sex,
inheritance, history of a transient ischemic attack (TIA)
or a previous stroke, hypertension, atherosclerosis, atrial
fibrillation, diabetes mellitus, smoking, alcohol abuse,
acute infections 1-2 months before stroke, and psycho-
logical stress. The latter was ascertained by self-report
in refuges from problematic regions of Georgia. Psycho-
logical stress was of interest to determine whether it can
influence the inflammatory markers or functional out-
come of the disease [5,6].
Upon admission, body temperature and blood pressure
were recorded. Next, chemistry, basic hematology, chest
X-rays, and electrocardiography were performed. Selected
patients did not display marked hyperthermia or infective
complications. Patients were managed according to evi-
dence-based stroke guidelines. Thrombolytics, hemodilu-
tion, corticoids, and Nimodipine were not applied.
Patients were strictly controlled and administered for
hypo- and hyperglycemia and hypertension. Antiplatelet
drugs were used in atherothrombotic and lacunar infarcts
and anticoagulants -in suspected cardioembolic infarcts
when the initial CT or magnetic resonance imaging (MRI)
scans did not show a large cerebral lesion.
The ischemic region was visualized at the twenty-
fourth hour from stroke onset by conventional magnetic
resonance imaging (MRI; magnet operating 1,5 Tesla,
Vision, Siemens) that provided axial T1, T2 images with
a slice thickness of 5 mm. Radiologists who were
blinded to study protocol defined the whole lesion
volume by multiplying the area of focal hyperintensity
by interslice gap. Stroke severity at admission and on
the seventh day was evaluated by the National Institute
Health Stroke Scale (NIHSS). Patients were divided in
two groups: Group 1 included the patients with severe
stroke (NIHSS ≥15) and Group 2 included the patients
with mild and moderate stroke (NIHSS <15) [7]. Func-
tional outcome was evaluated by Barthel Index at
1 month of stroke onset (BI) [8,9].
Immunological Assay
For special laboratory investigations, 10 ml of CSF was
taken from patients and controls at the sixth hour
from stroke onset. Eight-ml CSF samples were frozen
at -20°C for further assays, and the other 2 ml of CSF
were frozen in liquid nitrogen for electron paramagnet
resonance (EPR) study. CSF (5 ml) levels of the pro-
inflammatory cytokines: interleukin-1b(IL-1b), interleu-
kin-6(IL-6), tumor necrosis factor-a(TNF-a)a n dt h e
anti-inflammatory cytokine interleukin-10 (IL-10) were
detected by enzyme-linked immunosorbent assay
(ELISA), by application of ELISA- RIDER. The rela-
tionship between optical density and cytokine concen-
trations was defined using the standard curve
according to kit instructions (Bender Med systems
Diagnostics, Vienna, Austria).
Electron Paramagnetic Resonance (EPR) Study
Nitric oxide (NO) and lipoperoxide radical (LOO-) were
measured by EPR spin labeling (radiospectrophotometer
ESR-231 (X- band), with a modulation frequency of
50 KHZ and a TM-110 cavity). Diethyldithiocarbamic
acid (DETC) (Sigma) was used as an NO trap. CSF sam-
ples were incubated with Fe2+(DETC)2 stock solution.
The 0.8 mM Fe2+ (DETC) colloid solution formed was
yellow-brown in color and was used immediately after
preparation. EPR specters of NO-Fe2+ (DETC)2 com-
plexes were defined at the temperature of liquid nitro-
gen on a microwave power of 20 mVt. The amount of
detected NO was determined from the calibration curve
for integral intensity of the EPR signal of NOFe2+
(DETC)2, prepared at various concentrations (1-20 μM)
of the NO-donor MAHMANONOate [10]. LOO- trap,
a-phenil-tert-butilitron (PBN) (SIGMA) was used at a
dosage of 50 ml/0.5 ml CSF. EPR specters of LOO-
w e r ed e f i n e da tr o o mt e m p e r a t u r eo nam i c r o w a v e
p o w e ro f2 0m V t .E P Rs i g n a l so fL O O -w e r em e a s u r e d
in arbitrary units (a.u.) (signal intensity in millimeters
represented milliliters of CSF matter) [11].
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For nitrate (NO2) detection, 3 ml CSF samples were
processed by 20% Griess reagent. We used a CF-46
LOMO spectrophotometer for colorimetric detection.
Optical density was detected on a 540nm wavelength.
NaNO2 (5 μmol/L) was used for drawing the calibrating
curve [12].
Statistics
The obtained data were analyzed using SPSS 11.0 com-
puter software. Normally distributed continuous vari-
ables were compared with repeated measure ANOVA,
and the Kruskall-Wallis test compared abnormally dis-
tributed variables. The c
2-test was used to assess asso-
ciations among categorical variables. The effect of acetyl
salicylic acid (aspirin) and HMG-CoA reductase inhibi-
tors (statins) was separated by partial correlation analy-
sis. Spearman rank correlation and multiple logistic
regression (forward stepwise conditional model) was
used when all acute phase factors and stroke risk factors
were entered into the model. Aspirin and Statins
included in regression analysis as categorical covariate
variables. The Hosmer and Lemeshow test was used to
assess the goodness of fit of each model.
Results
The main characteristics of each clinical group are pre-
sented (Table 1). At the sixth hour from stroke onset,
the CSF proinflammatory cytokine levels in both study
groups were elevated compared to the control (P <
0.05). There was no significant difference in IL-1b and
TNF-a contents between the two groups, while Group 1
had significantly increased IL-6 contents compared with
Group 2 (P < 0.05). The anti-inflammatory cytokine IL-
10 levels were not significantly elevated in the two study
groups compared to the control (P < 0.07), although
t h e r ew a sat r e n dt o w a r d sa ni n c r e a s ei nG r o u p2
(Table 2).
The EPR signal intensity of NO was increased in
Groups 1 and 2 compared to the Control (P < 0.05), but
not between the study groups (P < 0.50) (Figure 1). The
EPR signal intensity of LOO- in Groups 1 and 2 was
significantly increased compared to the control (P <
0.05), and Group 1 had an elevated EPR signal intensity
of LOO- compared to Group 2 (P < 0.05) (Figure 2).
The NO2 levels for Group 2 were higher than those for
G r o u p1a n dt h ec o n t r o l s( T a b l e2 ) .A tt h et w e n t y -
fourth hour from stroke onset, the mean ischemic lesion
size (cm
3) for Group 1 was significantly increased as
compared to Group 2 (Table 1). There was a significant
positive correlation between the initial IL-6 contents
and ischemic lesion size (r = +0.34; P < 0.05). The effect
of Aspirin and Statins did not change the zero ordered
correlations between study variables. Multivariate
logistic regression analysis established a level of signifi-
cance of IL-6 contents toward the mean predicted prob-
ability of ischemic lesion size at the twenty-fourth hour
from stroke onset, after all the acute phase factors and
risk factors that we examined were entered into the
Table 1 Main Characteristics of ischemic stroke patients
of Group 1 and 2
Characteristics Group 1
(n = 44)
Group 2
(n = 51)
Male (%) 65 60
Age (years) 57.3 (12.2) 57.1 (12.9)
Inheritance (%) ** 37.8 14.7
History of TIA or previous stroke (%)** 18.9 6.4
History of myocardial infarction (%) 4.2 2.1
SBP, mm Hg 160.6(25.5) 165.8
(30.8)
DBP, mm Hg 90.2 (15.4) 92.4(14.6)
Body mass index, kg/m
2 27.2 (5.8) 28.4 (2.6)
Total/HDL cholesterol, ratio 4.3 (1.2) 3.9(1.4)
Triglycerides, mg/dL 136 (69) 131 (72)
C reactive protein, mg/L 3.9 (1.2) 3.1(0.6)
Atrial fibrillation (%) * 17.8 12.6
Serum glucose, mg/dL 157.1
(58.6)
156.2(59.9)
Smoking (%) 32.6 35.7
Alcohol abuse (%) 4.2 5.3
Acute infections 1-2 months before stroke
(%)
3.1 4.2
Psychological stress (%)* 17.8 11.5
Aspirin usage in current stroke % 32.6 34.8
HMG-CoA reductase inhibitors in current
stroke (%)
10.5 8.4
Fibrinogen, mg/dL 422.1
(100.2)
410.4
(106.8)
Leukocyte count, ×10
9/L 8.8 (2.2) 7.9 (2.6)
Temperature at admission (C°) 37.0 (1.4) 36.9(1.7)
Ischemic lesion volume (cm3)* 88.8 (11.7) 41.7 (9.6)
NIHSS score at admission ** 20.2 (4.1) 8.6 (4.9)
NIHSS score on 7
th day ** 18.5 (3.2) 7.3 (3.5)
Infarct topography
Cortical (%)** 30.5 17.8
Subcortical (%) ** 16.8 35.7
Stroke etiology
Large-artery atherosclerosis (%) 12.9 8.4
Cardioembolism (%)** 28.4 13.6
Small vessel occlusion (lacunar) (%)** 0 25.2
Other determined etiology (%) 3.1 2.1
Undetermined etiology (%) 3.1 4.2
Numbers represent mean (SD) or percentage as appropriate. NIHSS values
represent median (interquartil range).
*P < 0.05 ** P < 0.001.
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between the initial IL-6 CSF levels and the NIHSS
scores on the seventh day of stroke (r = +0.52; P <
0.05). There was no significant correlation between the
CSF inflammatory markers and cortical or sub-cortical
ischemic lesion sites. Researched factors found to be
dependent on each other once all of them were included
in stepwise logistic regression analysis toward the stroke
functional outcome. Only the initial IL-6 and NO2 levels
retained significance for functional outcome of stroke at
one month (Table 3), and cardiogenic strokes showed
borderline significance (P = 0.057). Effect and interac-
tions of Aspirin and Statins were not significant in the
given model. There was a negative correlation between
the initial IL-6 levels and functional outcome (BI) of
stroke at 1 month (r = - 0.45: P < 0.05).
Discussion
I ti sb e l i e v e dt h a tt h ef i r s tl ocal, glial immune response
of the brain tissue to acute ischemia is the connection
of CD4 T lymphocytes with astrocytes. Activated CD4
cells produce g-interferon, which stimulates astrocytes
to express HLA-II class antigens and to produce IL-1b.
The latter stimulates phagocyte activity in glial tissue
and induces production of IL-6 and TNF-a,t h ec y t o -
kines of initial local inflammatory reactions that trigger
the subsequent development of the pro- and anti-
inflammatory cytokine cascade [13].
Experimental and clinical studies have demonstrated
that the high CSF and blood concentrations of proin-
flammatory cytokines appear to reach a peak response
by 24-48 hours from stroke onset [14]. The present
study found elevated IL-1b,I L - 6a n dT N F - a level in
CSF at the sixth hour from ischemic stroke onset. Pre-
viously published studies have demonstrated that ele-
vated CSF and plasma levels of IL-1b correlate with
larger brain infarcts and worse functional outcome
[15,16]. The present study did not show any significant
group differences in the IL-1b and TNF-a CSF levels at
six hours of ischemic stroke. However, the absolute
number of these cytokines was elevated in the severe
stroke group, suggesting that they are of the first proin-
flammatory response and may trigger the subsequent
proinflammatory cascade.
The significant group differences in the initial IL-6
levels and the positive correlation with the size of the
ischemic region support earlier experimental and clinical
studies that revealed a correlation between increased
initial CSF and plasma IL-6 levels, on one hand, and lar-
ger brain lesion volume and poor outcome on the other
[17]. According to a number of experimental studies,
most animals retain high blood IL-6 levels during the
one-year period after ischemic brain injury. IL-6 has a
mitogenic effect on astrocytes and induces reactive glio-
sis in later stages of brain ischemia [18]. Thus, according
to the present research, IL-6 tends to reflect the severity
of the stroke even at six hours post-injury and may play
a key role in inflammatory damage caused by ischemia.
Previous experimental and clinical studies have shown
that a high initial expression of TNF-a is connected with
larger brain infarcts, and TNF-a knockout animals have
larger infarcts and decreased neuronal survival [19].
Expression of TNF-a during the critical period of a stroke
may restrict aggressive immune responses because the
TNF signaling pathway involving CD95-CD95L (ligand)
interactions is considered to be the controlling mechanism
of T cell expansion during the immune response [20].
Table 2 Comparison of selected CSF acute phase factors in clinical groups and control at the sixth hour from stroke
onset
IL-1b
(pg/ml)
IL-6
(pg/ml)
TNF-a
(pg/ml)
IL-10
(pg/ml)
NO2
(μmol/L)
NO
(μmol/L)
LOO
.
(a.u)
Control *0.95 ± 0.02 *1.9 ± 0.09 *14 ± 2.3 3.6 ± 1.2 *102 ± 15.9 *2.78 ± 0.16 0
Group I 34.14 ± 4.7 *58 ± 4.6 44 ± 5.4 5.9 ± 1.4 *121 ± 4.56 33.8 ± 7.1 *18 ± 4.1
Group II 30.4 ± 7.3 *21.8 ± 4.4 39.4 ± 9.4 7.1 ± 1.2 *158 ± 3.13 30.18 ± 6.8 *34 ± 7.1
Data are expressed as means (SD).
Figure 1 Comparison of EPR signal intensity of CSF free NO
between the study groups and control. Box plots represent
mean values (SD). P < 0.05 between the Group1, Group 2 and
control.
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TNF-a were found to be increased, but not significantly,
in severe stroke patients at the time point examined in
this study but might become significant at later stages of
stroke. Because we could not find a significant correla-
tion with these CSF markers and infarct size six hours
after stroke onset, we hypothesize that CSF IL-6 could
rapidly and specifically react in areas of ischemic
damage with increased activity at later time points and
retaining high meanings for a longer period. However,
further studies are necessary to confirm this hypothesis.
The anti-inflammatory cytokine IL-10 reaches its peak
expression between 2-7 days after stroke onset and lim-
its the production of proinflammatory agents through
negative feedback mechanisms [21]. We could not con-
firm previous studies where initial IL-10 levels in blood
were linked with infarct topography [22], which may be
due to the relatively short time for IL-10 expression
(6 hours). In keeping with previous studies, this study
also connected the borderline significance of cardioem-
bolic stroke to poor outcomes in selected patients,
which might be explained by the likely association of
elevated cardiac inflammatory markers in this stroke
subtype [23].
In conjunction with the release of pro-inflammatory
agents and glutamate toxicity, local inflammation, as
described above, results in free radical pathology that
directly and indirectly damages neurons by destabilizing
cell membranes, disintegrating DNA, and switching the
pathways of delayed neuronal death [24]. In the present
study, the high EPR signal intensity of free CSF NO may
be caused primarily by deregulation of the neuronal
form of NO-synthase. However, NO produced by indu-
cible and endothelial forms of NO-synthase can also
pass the damaged blood-brain barrier and accumulate in
CSF. The toxic effects of NO in the ischemic brain
depend on the cellular ratio of NO/O2
- and the exis-
tence of growth factors in the surrounding tissues. The
high EPR signal intensity resulting from the cell mem-
brane lipids’ degradation product, lipoperoxide radicals,
LOO-, and the increased level of IL-6 in Group 1 indi-
cates a prevalence of oxidative stress in severe stroke
patients. In conditions where NO is more prevalent
than superoxide anion (O2-), NO toxicity in neurons is
decreased by restoration of peroxinitrite (ONOO-) to
NO2 [25,26]. The increased concentrations of NO2 in
Group 2 patients and the relatively diminished EPR sig-
nals of LOO- indicate conditions in which NO can act
as an antioxidant. The protective response of NO can
also be obtained through nitrosonium (NO
+), which
nitrosylates the thiol groups of glutamate receptors and
thus diminishes glutamate toxicity [27].
The limitation of this study is that we lack a compre-
hensive understanding of the complex action of NO in
the blood and CSF in the acute stage of ischemic stroke.
The initial endothelial NO expressed in the blood might
Figure 2 Comparison of EPR signal intensity of CSF free LOO-
between the study groups and control. Box plots represent
mean values (SD). P < 0.05 between the study groups and control.
P < 0.50 between the Group 1 and Group 2.
Figure 3 Relation of initial CSF IL-6 content with ischemic
lesion size 24 hours from stroke. After all acute phase factors and
risk factors entered into the stepwise model of multivariate logistic
regression only initial CSF IL-6 gained significance and positively
correlated with mean predicted probability of brain ischemic lesion
size (r = +0.34; P < 0.05).
Table 3 Relationship between selected acute phase
factors and functional outcome of stroke at one month
CSF Acute phase
factors
Regression
Coefficient
Standard
Error
P Value
IL-6 3.08 0.014 0.031
NO2 8.06 2.14 0.001
(Multivariate logistic regression analysis).
Only variables statistically significant in the final model are shown.
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ability to improve microhaemorheology [28]. Addition-
ally, whether the CSF cytokine levels are dependent
upon serum/blood concentrations and the blood-CSF
barrier function and whether the CSF markers are
synthesized purely intrathecally has yet to be evaluated.
Conclusions
The results of the present investigation demonstrate that
nitrate (NO2) content in the CSF appears to reflect the
severity of the oxidative stress reaction that develops in
the ischemic neurovascular unit in the first hours of
stroke and can predict functional outcome. CSF IL-6
content seems to be the most reliable prognostic indica-
tor in the acute phase of ischemic stroke, with regard to
the probability of infarct size, the clinical course of dis-
ease and the functional outcome of stroke at one
month.
Acknowledgements
Study is supported by an INTAS collaborative research grant and the
Georgian Academy of Sciences. The sponsors had no role in study design,
data collection, data analysis, data interpretation, or writing of the
manuscript.
Author details
1Department of Neuromedicine, Tbilisi State Medical University, Tbilisi,
Georgia.
2Department of Biophysics and Biochemistry, Tbilisi State Medical
University, Tbilisi, Georgia.
3Department of Neurology, Tel-Aviv Sourasky
Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv,
Israel.
Authors’ contributions
MB designed the study, interpreted the data and drafted the manuscript. TS
carried out the immunoassays and EPR analysis. RS participated in
acquisition of data, interpretation and statistical analysis. NI conducted the
additional statistics and interpreted the data. NB revised critically the
intellectual content and gave the final approval for the given version of
manuscript.
All authors read and approved the final manuscript.
Authors’ Information
MB Associated Professor of Neurology MD, PhD. Department of
Neuromedicine, Tbilisi State Medical University, Tbilisi, Georgia.
TS Full Professor of Biophysics PhD. Department of Biophysics and
Biochemistry, Tbilisi State Medical University, Tbilisi, Georgia
RS Full Professor of Neurology MD, PhD. Department of Neuromedicine,
Tbilisi State Medical University, Tbilisi, Georgia.
NI Associated Professor of Biophysics, PhD, Head of Medical Statistics Section
of the Department of Biophysics and Biochemistry, Tbilisi State Medical
University, Tbilisi, Georgia
NB Full Professor of Neurology, MD. Department Head, Tel-Aviv Sourasky
Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv,
Israel
Competing interests
The authors declare that they have no competing interests.
Received: 1 September 2010 Accepted: 30 March 2011
Published: 30 March 2011
References
1. Aktas O, Ullrich O, Infante-Duarte C, Nitsch R, Zipp F: Neuronal damage in
brain inflammation. Arch Neurol 2007, 64(2):185-189.
2. Cherubini A, Ruggiero C, Polidori MC, Mecocci P: Potential markers of
oxidative stress in stroke. Free Rad Biol Med 2005, 39:841-852.
3. The European Stroke Organization (ESO) Executive Committee and the ESO
Writing Committee: Guidelines for Management of Ischaemic Stroke and
Transient Ischaemic Attack. Cerebrovasc Dis 2008, 25:457-507.
4. Adams HP, Bendixen BH, Kapelle LJ, the TOAST investigators: Classification
of subtypes of acute ischemic stroke. Definitions for use of multicenter
clinical trial TOAST. Stroke 1993, 24:35-41.
5. Jood K, Redfors P, Rosengren A, Blomstrand CH, Jern CH: Self-perceived
psychological stress and ischemic stroke: a case-control study. BMC
Medicine 2009, 7:53.
6. Truelsen T, Nielsen N, Boysen G, Grønbæk M: Self-Reported Stress and Risk
of Stroke, The Copenhagen City Heart Study. Stroke 2003, 34:856-862.
7. Adams HP, et al: NIHSS and Patient Outcomes. Neurology 1999,
53:126-131.
8. Dromerick AW, Edwards DF, Diringer MN: Sensitivity to changes in
disability after stroke: A comparison of four Scales useful in clinical trials.
Journal of Rehabilitation Research and Development 2003, 40(1):1-8.
9. Govan L, Langhorne P, Weir CJ: Categorizing stroke prognosis using
different stroke scales. Stroke 2009, 40(10):3396-9.
10. Fink B, Fink N: EPR techniques for detection of nitric oxide in vivo as an
index of endothelial disfunction. Pharmacological reports 2006, 58:8-15.
11. Richardson SRussell, Donato AJ, Uberoi AD, Wray W, Lawrenson L,
Nishiyama S, Bailey DM: Exercise-induced brachial artery vasodilation: role
of free radicals. Am JPhysiol Heart Circ Physiol 2007, 292:1516-1522.
12. Guevara I, Iwanejko J, Dembinska-Kiec A, et al: Determination of nitrite/
nitrate in human biological material by the sample Griess reaction. Clin
Chim Acta 1998, 274:177-88.
13. Schroeter M, Jander S, Witte OW, Stoll G: Local immune responses in the
rat cerebral cortex after middle cerebral artery occlusion. J
Neuroimmunol 1994, , 55: 195-203.
14. Fassbender K, Rossol S, Kammer T, et al: Proinflammatory cytokines on the
serum of patients with acute cerebral ischemia, kinetics and secretion
and relation to the extent of brain damage and outcome of disease. J
neurol Sci 1994, 122:135-139.
15. Garcia JH, Liu KF, Relton JK: Interleukin-1 receptor antagonist decreases
the number of necrotic neurons in rats with middle cerebral artery
occlusion. Am J Pathol 1995, 147:1477-1486.
16. Chamorro A, Hallenbeck J: The harms and benefits of inflammatory and
immune responses in vascular disease. Stroke 2006, 37:291-293.
17. Smith CJ, Emsley HCA, Gavin CM, et al: Peak plasma interleukin-6 and
other peripheral markers of inflammation in the first week of ischemic
stroke correlate with brain infarct volume. stroke severity, and long-term
outcome. BMC Neurol 2004, 4:2-9.
18. Emsley HCA, Smith CJ, Georgiou RF, Vail A, Tyrrell P-J, Barberen E-M, et al:
Correlation of systemic inflammatory response with infarct volume in
acute ischemic patients Response. Stroke 2005, 36(2):228-229.
19. Barone FC, Arvin B, White RF, et al: Tumor necrosis factor-a a mediator of
focal ischemic brain injury. Stroke 1997, 28:1233-1244.
20. Martin-Villaba A, Herr I, Jeremias I, et al: CD95 ligand (Fas-L/APO-1L) and
tumor necrosis factor-related apoptosis-inducing ligand mediate
ischemia-induced apoptosis in neurons. J Neurosci 1999, 19:3809-3817.
21. Dietrich ND, Busto R, Bethea JR: Postischemic hypothermia and IL-10
treatment provide long-lasting neuroprotection of CA1 hippocampus
following transient global ischemia in rats. Exp Neurol 1999, 158:444-450.
22. Spera PA, Ellison JA, Feurstein GZ, Barone FC: IL-10 reduces rat brain injury
following focal stroke. Neurosci Lett 1998, 251:189-192, 24.
23. Chong WL, Sengupta A, Sandercock P: Blood Markers for the Prognosis of
Ischemic Stroke: A Systematic Review. Stroke 2009, 40:380-389.
24. Kunz A, Park L, Abe T, Gallo EF, Anrather J, Zhou P, Iadecola C:
Neurovascular protection by ischemic tolerance: Role of Nitric Oxide and
Reactive Oxygen Species. J Neurosci 2007, 27(27):7083-7093.
25. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med
1993, , 329:: 2002-2012.
26. Ignarro LJ: Signal transduction mechanisms involving nitric oxide.
Biochem Pharmacol 1991, 41:485-490.
27. Orio D, Kunz A, Kawano T, Anrather J, Zhou P, Iadecola C:
Lipopolysaccharide Induces Early Tolerance to Excitotoxicity via Nitric
Oxide and cGMP. Stroke 2007, 38(10):2812-2817.
28. Lavi SH, Egbarya R, Lavi R, Jacob G: Role of Nitric Oxide in the Regulation
of Cerebral Blood Flow in Humans. Circulation 2003, 107:1901.
Beridze et al. BMC Neurology 2011, 11:41
http://www.biomedcentral.com/1471-2377/11/41
Page 6 of 7Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/41/prepub
doi:10.1186/1471-2377-11-41
Cite this article as: Beridze et al.: Selected acute phase CSF factors in
ischemic stroke: findings and prognostic value. BMC Neurology 2011
11:41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Beridze et al. BMC Neurology 2011, 11:41
http://www.biomedcentral.com/1471-2377/11/41
Page 7 of 7